NUT癌中的新型BRD2::NUTM1融合，对化疗反应特殊：病例报告

IF 3 Q2 ONCOLOGY JTO Clinical and Research Reports Pub Date : 2024-01-01 DOI:10.1016/j.jtocrr.2023.100625

Sarah J. Wu MD, PhD , Justin J. Kim GED , Yeying Huang BS , R. Taylor Durall BS , Simone Becker RN , Stephanie Canty CNP, MSN , Stefania Molinaro BS , Evan Pisick MD , Geoffrey I. Shapiro MD, PhD , Christopher A. French MD , Jia Luo MD

{"title":"NUT癌中的新型BRD2::NUTM1融合，对化疗反应特殊：病例报告","authors":"Sarah J. Wu MD, PhD , Justin J. Kim GED , Yeying Huang BS , R. Taylor Durall BS , Simone Becker RN , Stephanie Canty CNP, MSN , Stefania Molinaro BS , Evan Pisick MD , Geoffrey I. Shapiro MD, PhD , Christopher A. French MD , Jia Luo MD","doi":"10.1016/j.jtocrr.2023.100625","DOIUrl":null,"url":null,"abstract":"<div><p>We present the first known case of a patient with <em>BRD2::NUTM1</em>-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a <em>BRD2::NUTM1</em> fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364323001686/pdfft?md5=5196d7d17fc051b503b55fe9e7f25b4e&pid=1-s2.0-S2666364323001686-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report\",\"authors\":\"Sarah J. Wu MD, PhD , Justin J. Kim GED , Yeying Huang BS , R. Taylor Durall BS , Simone Becker RN , Stephanie Canty CNP, MSN , Stefania Molinaro BS , Evan Pisick MD , Geoffrey I. Shapiro MD, PhD , Christopher A. French MD , Jia Luo MD\",\"doi\":\"10.1016/j.jtocrr.2023.100625\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We present the first known case of a patient with <em>BRD2::NUTM1</em>-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a <em>BRD2::NUTM1</em> fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001686/pdfft?md5=5196d7d17fc051b503b55fe9e7f25b4e&pid=1-s2.0-S2666364323001686-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364323001686\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364323001686","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们介绍了第一例已知的BRD2::NUTM1驱动的NUT癌患者。一名 59 岁的女性患者因分化不良的鳞状细胞肺癌转移至胸膜而就诊。最终，经NUT免疫组化阳性、NUT荧光原位杂交和BRD2::NUTM1融合的RNA新一代测序，确诊为NUT癌。她接受了多线化疗，但均有反应，确诊后两年仍健在。本报告扩展了已知的 NUT 癌融合基因，并强调了根据基因融合伙伴的不同，患者预后可能存在的差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

We present the first known case of a patient with BRD2::NUTM1-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a BRD2::NUTM1 fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊